GCP
VERA icon

GSA Capital Partners’s Vera Therapeutics VERA Stock Holding History

GSA Capital Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,686
Closed -$229K – 2194
2026
Q1 		$229K Buy
+5,686
New +$245K 0.01% 1394
2025
Q1 		– Sell
-12,778
Closed -$540K – 2103
2024
Q4 		$540K Buy
12,778
+665
+5% +$29.4K 0.04% 831
2024
Q3 		$535K Sell
12,113
-20,287
-63% -$770K 0.04% 858
2024
Q2 		$1.17M Buy
+32,400
New +$1.29M 0.08% 402
2024
Q1 		– Sell
-52,590
Closed -$809K – 1993
2023
Q4 		$809K Buy
52,590
+22,620
+75% +$287K 0.07% 506
2023
Q3 		$411K Buy
+29,970
New +$514K 0.04% 912
2023
Q2 		– Sell
-16,272
Closed -$126K – 1963
2023
Q1 		$126K Buy
+16,272
New +$126K 0.01% 1329

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSA Capital Partners's VERA Position: Q2 2026 in Review

GSA Capital Partners sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 5,686 shares — an estimated $229K sold.

GSA Capital Partners first reported a position in VERA in Q1 2023 and held it in 7 quarters. The position peaked at $1.17M in Q2 2024. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • GSA Capital Partners reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 5,686 Vera Therapeutics shares in Q2 2026, an estimated $229K.
  • GSA Capital Partners first reported a position in Vera Therapeutics in Q1 2023 and held it in 7 quarters.
  • GSA Capital Partners's Vera Therapeutics position peaked at $1.17M in Q2 2024.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.